Full text
LAY SUMMARY
Pneumocystis jirovecii pneumonia (PJP) is a life-threatening infection occurring in patients receiving bendamustine and the incidence, especially when attempting diagnosis with a new technology, remains unknown. Our retrospective study showed a 1.7% cumulative incidence of PJP in patients receiving bendamustine-based therapy, which is below the accepted 3.5% threshold for universal prophylaxis. Prior stem cell transplant, prior chemotherapy within 1 year of bendamustine initiation, and lack of concurrent chemotherapy were associated with the development of PJP. Anti-Pneumocystis prophylaxis was not significantly associated with a reduction in PJP compared to no prophylaxis.
INTRODUCTION
Pneumocystis jirovecii pneumonia (PJP) is a severe, opportunistic infection that has historically been found in patients who are infected with human immunodeficiency virus (HIV) or who are immunosuppressed with high doses of corticosteroids.1 PJP has been increasingly identified in patients with malignancies, especially hematological malignancies, who are prescribed immunosuppressive chemotherapy regimens.1,2 HIV seronegative patients who develop PJP, especially with a cancer diagnosis, tend to have higher mortality (30%–60%) compared to those infected with HIV (10%–20%).3–5
Prophylaxis regimens for PJP are well established for HIV-infected patients with T-helper cell count (CD4+) less than 200 cells/mm3 and for patients taking high doses of corticosteroids; however, the indication for anti-Pneumocystis prophylaxis is less clear in other immunosuppressed patient populations.2,6 One meta-analysis suggests initiating prophylaxis when risk for PJP is greater than 3.5%, a threshold which has been widely adapted for PJP research and included in antimicrobial prophylaxis guidelines.7,8 Others have recommended routine anti-Pneumocystis prophylaxis be provided when the incidence of PJP is 3–5% or higher.9
Bendamustine is a nitrogen mustard derivative with alkylating properties that was initially approved by the FDA in 2008 for treatment of chronic lymphocytic leukemia (CLL).10,11 Efficacy demonstrated in the treatment of other hematologic malignancies has propagated use as frontline, second-line, or salvage therapy.12 Reports describing PJP development in patients on bendamustine therapy appeared as early as 2003.13–19 Bendamustine has been shown to decrease CD4+ counts, with return to baseline levels taking as long as 7–9 months following the completion of treatment.15,16,18,20 Despite these findings, there is no clear recommendation for anti-Pneumocystis prophylaxis for patients receiving bendamustine.8,21,22 A recent Surveillance, Epidemiology, and End Results (SEER)–Medicare cohort study of over 1,200 patients with indolent Non-Hodgkin lymphomas reported that those treated with bendamustine had a significantly increased risk of opportunistic infections, although PJP risk was only significantly increased when bendamustine was used as a third-line therapy (HR 3.32, 95% CI 1.00-11.11).23
Recommendations for anti-Pneumocystis prophylaxis in patients on bendamustine therapy rely on an appropriately defined incidence using contemporary diagnostic techniques. PJP was historically diagnosed by respiratory sample analysis via Giemsa or Giemsa-like rapid stains, Gomori methenamine silver stain, toluidine blue O stain, and fluorescein-conjugated monoclonal antibody (direct fluorescent-antibody [DFA] stain).2 Techniques used in the systematic review and meta-analysis that helped define the 3.5% threshold for prophylaxis relied upon microbiological or histopathological evaluation of respiratory samples or lung biopsies with some included studies utilizing direct demonstration by monoclonal antibodies or silver stain.7 However, PCR-based techniques for respiratory sample analysis have demonstrated improved sensitivity compared to other methods, and the use of positive Pneumocystis PCR in conjunction with clinical evaluation has become the more common method of diagnosis.24–27 The purpose of this study is to determine the incidence of PJP diagnosed by single copy target, non-nested PCR in patients receiving bendamustine. Results from this investigation will guide future decision-making surrounding anti-Pneumocystis prophylaxis in this patient population.
METHODSThis is a retrospective, observational cohort study of adults aged 18 years and older who received at least one dose of bendamustine between 1 January 2006 and 1 August 2019 at a large academic health center. Patients were excluded if they were HIV seropositive, refused research consent, or were considered part of a vulnerable population. The study was reviewed by the local Institutional Review Board (IRB) and determined to be exempt from the requirement for IRB approval (IRB #19-007217, Approval Date: 20 September 2019). After inclusion, an electronic health record (EHR) review was performed in accordance with the ethical standards of the 1964 Declaration of Helsinki with adherence to all relevant regulations of the US Health Insurance Portability and Accountability Act.
Demographic data, laboratory values, cancer diagnosis, medication administrations, PJP diagnosis with supporting Pneumocystis PCR and radiographic imaging results, and patient outcomes were abstracted from the patient EHR utilizing a standardized data collection form and managed with REDCap (Research Electronic Data Capture).28 Cancer diagnosis with subtyping was according to World Health Organization (WHO) classification criteria and prior to systemic chemotherapy.29 Diagnosis of PJP was collected from initiation of bendamustine through 9 months after the last dose of bendamustine. A positive Pneumocystis PCR using our single copy gene-targeted, non-nested, real-time PCR assay from a respiratory sample in conjunction with clinical signs and symptoms of pulmonary compromise on medical record review constituted a diagnosis of PJP. The detection threshold of this PCR diagnostic assay was set to detect active PJP, minimizing potential false positives caused by Pneumocystis colonization, and with overall sensitivity exceeding 96%.24,26 The initial development and the quantitative PCR methods and conditions were described previously and set a quantitative threshold at 45 cycles.24,26
Data pertaining to patient demographics and clinical characteristics were summarized with descriptive statistics. These included counts and percentages for categorical and ordinal variables and medians and interquartile ranges (IQR) for continuous variables. The cumulative incidence of PJP was estimated using the Aalen–Johansen method where death was a competing risk. Cox proportional hazards regression was used to demonstrate the strength of association between the independent variables and risk of PJP. These associations were summarized with hazard ratios (HR) and 95% confidence intervals (CI). All analyses were carried out using SAS (Version 9.4, SAS Institute Inc., Cary, NC). A P value less than 0.05 was considered statistically significant.
RESULTSA total of 486 patients met inclusion criteria and were included in the analysis. The median patient age was 66 years (range 20–94) and 294 (60.5%) were male. Patients were mostly Caucasian (n = 457, 94.0%). The most common diagnosis was follicular lymphoma (n = 180, 37.0%) according to WHO classification criteria. Additional baseline demographic and laboratory information for the study population is summarized in Table 1.
TABLE 1 Baseline characteristics and laboratory values
| Characteristic | Patients with PJP (n = 8) | Patients without PJP (n = 478) |
Total (n = 486) |
| Age, years, median (range) | 69 (36–76) | 66 (20–94) | 66 (20–94) |
| Male, No. (%) | 4 (50.0) | 290 (60.7) | 294 (60.5) |
| Race, No. (%) | |||
| Caucasian | 8 (100.0) | 449 (93.9) | 457 (94.0) |
| Other | 0 (0.0) | 29 (6.1) | 29 (6.0) |
| Body Surface Area, m2, median (IQR) | 2.04 (1.72–2.23) | 1.97 (1.79–2.15) | 1.97 (1.79–2.15) |
| Body Mass Index, kg/m2, median (IQR) | 27.0 (23.9–29.7) | 27.2 (23.8–31.4) | 27.2 (23.8–31.4) |
| Cancer Diagnosis, No. (%) | |||
| Follicular lymphoma | 3 (37.5) | 177 (37.0) | 180 (37.0) |
| Mantle cell lymphoma | 1 (12.5) | 77 (16.1) | 78 (16.0) |
| Marginal zone lymphoma | 0 (0.0) | 55 (11.5) | 55 (11.3) |
| Diffuse large B-cell lymphoma | 0 (0.0) | 44 (9.2) | 44 (9.1) |
| Waldenström macroglobulinemia | 0 (0.0) | 41 (8.6) | 41 (8.4) |
| Chronic lymphocytic leukemia/small lymphocytic lymphoma | 0 (0.0) | 21 (4.4) | 21 (4.3) |
| Other | 4 (50.0) | 63 (13.2) | 67 (13.8) |
| Phase of Diagnosis - Primary, No. (%) | 8 (100.0) | 440 (92.1) | 448 (92.2) |
| Charlson Comorbidity Index, median (range) | 5.5 (4–13) | 5 (0–19) | 5 (0–19) |
| COPD, No. (%) | 0 (0.0) | 40 (8.4) | 40 (8.2) |
| CKD, No. (%) | 1 (12.5) | 74 (15.5) | 75 (15.4) |
| ESLD, No. (%) | 0 (0.0) | 2 (0.4) | 2 (0.4) |
| Solid Organ Transplant, No. (%) | 0 (0.0) | 3 (0.6) | 3 (0.6) |
| Stem Cell Transplant, No. (%) | 3 (37.5) | 48 (10.0) | 51 (10.5) |
| Autologous | 2 (25.0) | 43 (9.0) | 45 (9.3) |
| Allogeneic | 1 (12.5) | 5 (1.0) | 6 (1.2) |
| Autoimmune Disease, No. (%) | 1 (12.5) | 19 (4.0) | 20 (4.1) |
| Rheumatoid Arthritis | 1 (12.5) | 9 (1.9) | 10 (2.1) |
| Systemic lupus erythematosus | 0 (0.0) | 7 (1.5) | 7 (1.4) |
| Inflammatory Bowel/Crohn’s Disease | 0 (0.0) | 4 (0.8) | 4 (0.8) |
| WBC count, ×109/L, median (IQR) | 7.5 (4.7–9.7) | 6.5 (4.9–9.6) | 6.5 (4.8–9.6) |
| Hgb, g/dL, median (IQR) | 10.2 (9.9–11.6) | 12.0 (9.9–13.5) | 12.0 (9.9–13.5) |
| ANC, ×109/L, median (IQR) | 4.81 (3.35–5.29) | 3.82 (2.65–5.15) | 3.82 (2.66–5.16) |
| ALC, ×109/L, median (IQR) | 1.15 (0.72–1.55) | 1.17 (0.71–1.85) | 1.17 (0.71–1.84) |
| Serum Creatinine, mg/dL, median (IQR) | 1.1 (0.8–1.1) | 1.0 (0.8–1.2) | 1.0 (0.8–1.2) |
| Estimated Creatinine Clearance, No. (%) | |||
| >60 mL/min | 5 (62.5) | 304 (65.2) | 309 (65.2) |
| 31–60 mL/min | 3 (37.5) | 138 (29.6) | 141 (29.7) |
| <31 mL/min | 0 (0.0) | 24 (5.2) | 24 (5.1) |
| BUN, mg/dL, median (IQR) | 18 (18–19) | 18 (13–26) | 18 (13–25) |
| ALT, units/L, median (IQR) | 21 (19–23) | 21 (16–32) | 21 (16–31) |
| AST, units/L, median (IQR) | 25 (21–31) | 25 (20–34) | 25 (20–34) |
| ALP, units/L, median (IQR) | 79 (60–105) | 81.5 (66–104) | 81.5 (66–104) |
| Total Bilirubin, mg/dL, median (IQR) | 0.7 (0.4–0.9) | 0.5 (0.3–0.7) | 0.5 (0.3–0.7) |
| Direct Bilirubin, mg/dL, median (IQR) | 0.3 (0.3–0.3) | 0.2 (0.1–0.3) | 0.2 (0.1–0.3) |
| Albumin, g/dL, median (IQR) | 3.5 (3.5–3.6) | 3.5 (3.1–3.9) | 3.5 (3.1–3.8) |
| LDH, units/L, median (IQR) | 233 (202–278) | 206 (168–278) | 206 (168–278) |
Abbreviations: ALC, absolute lymphocyte count; ALP, alkaline phosphatase; ALT, alanine transaminase; ANC, absolute neutrophil count; AST, aspartate transaminase; BUN, blood urea nitrogen; CI, confidence interval; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; ESLD, end stage liver disease; IQR, interquartile range; LDH, lactate dehydrogenase; PJP, Pneumocystis jirovecii pneumonia; WBC, white blood cell.
Bendamustine was provided as first-line therapy in 297 (61.1%) patients, second-line in 68 (14.0%) patients, and salvage beyond second-line in 121 (24.9%) patients. The majority of patients (n = 461, 94.9%) received bendamustine-based combination therapy, and 25 (5.1%) patients received bendamustine monotherapy. Detailed information about the bendamustine-based chemotherapy regimens prescribed is available in Table S1. The most common treatment administered in conjunction with bendamustine was rituximab (n = 431, 88.7%). A total of 225 (46.3%) patients completed six cycles of bendamustine with 215 (44.2%) patients receiving 12 doses of bendamustine. The median cumulative dose of bendamustine was 805 mg/m2 (IQR 437–1080). Steroids were prescribed to 377 (77.6%) patients during bendamustine therapy, and 13 (2.7%) patients received additional immunosuppressive medications including: sirolimus (n = 4), tacrolimus (n = 4), cyclosporine (n = 3), mycophenolate mofetil (n = 3), everolimus (n = 2), and azathioprine (n = 1). In the 9-month post-bendamustine observation, 175 (36.0%) patients received additional therapy for treatment of their malignant disease; 78 (44.6%) of these patients received rituximab maintenance. Additional detail regarding chemotherapy and immunotherapy use is provided in Table 2.
TABLE 2 Chemotherapy characteristics and medication use
| Characteristics | Patients with PJP (n = 8) | Patients without PJP (n = 478) | Patients (n = 486) |
| Line of chemotherapy, No. (%) | |||
| 1 | 4 (50.0) | 293 (61.3) | 297 (61.1) |
| 2 | 0 (0.0) | 68 (14.2) | 68 (14.0) |
| ≥3 | 4 (50.0) | 117 (24.5) | 121 (24.9) |
| Prior chemotherapy within one year, No. (%) | 4 (50.0) | 118 (24.7) | 122 (25.1) |
| Chemotherapy most immediately prior to bendamustine within 1 year, No. (%) | |||
| R-CHOP | 0 (0.0) | 14 (11.9) | 14 (11.5) |
| Rituximab monotherapy | 0 (0.0) | 13 (11.0) | 13 (10.7) |
| R-CVP | 0 (0.00) | 5 (4.2) | 5 (4.1) |
| Rituximab and methylprednisolone | 0 (0.0) | 5 (4.2) | 5 (4.1) |
| Other | 4 (100.0) | 81 (68.6) | 85 (69.7) |
| Cumulative bendamustine dose, mg/m2, median (IQR) | 650 (450–1010) | 810 (437–1080) | 805 (437–1080) |
| Chemotherapy cycles, median (range) | 4.5 (1–6) | 5 (1–10) | 5 (1–10) |
| Chemotherapy cycles, No. (%) | |||
| 1 | 2 (25.0) | 64 (13.4) | 66 (13.6) |
| 2 | 0 (0.00) | 46 (9.6) | 46 (9.5) |
| 3 | 2 (25.0) | 47 (9.8) | 49 (10.1) |
| 4 | 0 (0.0) | 68 (14.2) | 68 (14.0) |
| 5 | 0 (0.0) | 26 (5.4) | 26 (5.3) |
| ≥6 | 4 (50.0) | 227 (47.5) | 231 (47.5) |
| Concurrent chemotherapy, No. (%) | 4 (50.0) | 457 (95.6) | 461 (94.9) |
| Rituximab | 3 (37.5) | 428 (89.5) | 431 (88.7) |
| Bortezomib | 0 (0.0) | 13 (2.7) | 13 (2.7) |
| Brentuximab | 0 (0.0) | 10 (2.1) | 10 (2.1) |
| Lenalidomide or thalidomide | 0 (0.0) | 10 (2.1) | 10 (2.1) |
| Other | 1 (12.5) | 24 (5.0) | 25 (5.1) |
| Steroids received, No. (%) | 8 (100.0) | 369 (77.2) | 377 (77.6) |
| Receipt of additional chemotherapy within nine months after completion of bendamustine, No. (%) | 4 (50.0) | 171 (35.8) | 175 (36.0) |
| Rituximab monotherapy | 1 (25.0) | 77 (45.0) | 78 (44.6) |
| Other | 3 (75.0) | 94 (55.0) | 97 (55.4) |
| Additional immunosuppression, No. (%) | 1 (12.5) | 12 (2.5) | 13 (2.7) |
| Number of additional immunosuppressants, median (range) | 1 (1–1) | 1 (1–3) | 1 (1–3) |
| Anti-Pneumocystis prophylaxis, No. (%) | 1 (12.5) | 143 (29.9) | 144 (29.6) |
Abbreviations: CI, confidence interval; IQR, interquartile range; PJP, Pneumocystis jirovecii pneumonia; R-CHOP, rituximab/cyclophosphamide/doxorubicin/vincristine/prednisone; R-CVP, rituximab/cyclophosphamide/vincristine/prednisone; RICE, rituximab/ifosfamide/ carboplatin/etoposide.
Association of baseline characteristics, laboratory values, chemotherapy, and concurrent immunosuppressive medication use with the occurrence of PJP is presented in Table 3. Stem cell transplant (SCT) occurring any time prior to bendamustine initiation and prior chemotherapy within 1 year of bendamustine initiation were significantly associated with the development of PJP in univariate analyses. Interestingly, concurrent chemotherapy was associated with a decreased risk of being diagnosed with PJP. Steroids and additional, non-chemotherapy immunosuppressive medications did not have a statistically significant association with the development of PJP infection.
TABLE 3 Association of baseline characteristics, laboratory values, chemotherapy, and medication use with occurrence of PJP
| Characteristic | Hazard Ratio | 95% CI | p |
| Age, years, median (range) | 0.98a | 0.58–1.64 | 0.93 |
| Male, No. (%) | 0.68 | 0.17–2.74 | 0.59 |
| Race, No. (%) | |||
| Caucasian | 1.02 | 0.13–132.20 | 0.99 |
| Other | Reference | ||
| Body Surface Area, m2, median (IQR) | 1.01b | 0.79–1.29 | 0.95 |
| Body Mass Index, kg/m2, median (IQR) | 0.97 | 0.86–1.10 | 0.65 |
| Phase of Diagnosis - Primary, No. (%) | 1.30 | 0.16–168.72 | 0.85 |
| Charlson Comorbidity Index, median (range) | 1.06 | 0.88–1.28 | 0.53 |
| COPD, No. (%) | 0.68 | 0.01–5.45 | 0.78 |
| CKD, No. (%) | 0.85 | 0.11–6.94 | 0.88 |
| ESLD, No. (%) | 33.12 | 0.25–280.23 | 0.11 |
| Solid organ transplant, No. (%) | 11.74 | 0.09–94.23 | 0.22 |
| Stem cell transplant, No. (%) | 6.83 | 1.63–28.69 | 0.009 |
| Autoimmune Disease, No. (%) | 3.05 | 0.37–24.76 | 0.30 |
| WBC count, ×109/L, median (IQR) | 0.99 | 0.94–1.04 | 0.65 |
| Hgb, g/dL, median (IQR) | 0.84 | 0.62–1.13 | 0.24 |
| ANC, ×109/L, median (IQR) | 1.04 | 0.82–1.31 | 0.74 |
| ALC, ×109/L, median (IQR) | 0.69 | 0.27–1.76 | 0.44 |
| Serum Creatinine, mg/dL, median (IQR) | 0.91 | 0.26–3.13 | 0.88 |
| BUN, mg/dL, median (IQR) | 0.96 | 0.85–1.08 | 0.51 |
| ALT, units/L, median (IQR) | 0.97 | 0.89–1.06 | 0.55 |
| AST, units/L, median (IQR) | 1.00 | 0.95–1.04 | 0.82 |
| ALP, units/L, median (IQR) | 1.00a | 0.90–1.12 | 0.97 |
| Total Bilirubin, mg/dL, median (IQR) | 1.04b | 0.9601.13 | 0.34 |
| Direct Bilirubin, mg/dL, median (IQR) | 0.99b | 0.76–1.29 | 0.95 |
| Albumin, g/dL, median (IQR) | 0.98b | 0.75–1.28 | 0.86 |
| LDH, units/L, median (IQR) | 0.97c | 0.69–1.38 | 0.88 |
| Prior chemotherapy within one year, No. (%) | 4.55 | 1.13–18.31 | 0.033 |
| Cumulative bendamustine dose, mg/m2, median (IQR) | 0.87a | 0.71–1.07 | 0.19 |
| Chemotherapy cycles, median (range) | 0.81 | 0.56–1.17 | 0.26 |
| Concurrent chemotherapy, No. (%) | 0.03 | 0.01–0.13 | <0.001 |
| Steroids received, No. (%) | 5.54 | 0.69–716.01 | 0.13 |
| Receipt of additional chemotherapy within nine months after bendamustine, No. (%) | 1.65 | 0.41–6.60 | 0.48 |
| Additional immunosuppression, No. (%) | 5.79 | 0.71–47.09 | 0.10 |
| Anti-Pneumocystis prophylaxis, No. (%) | 0.37 | 0.05–3.04 | 0.36 |
Abbreviations: ALC, absolute lymphocyte count; ALP, alkaline phosphatase; ALT, alanine transaminase; ANC, absolute neutrophil count; AST, aspartate transaminase; BUN, blood urea nitrogen; CI, confidence interval; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; ESLD, end stage liver disease; IQR, interquartile range; LDH, lactate dehydrogenase; PJP, Pneumocystis jirovecii pneumonia; WBC, white blood cell.
aHazard ratios for continuous variable are per 10 unit increase.
bHazard ratios for continuous variable are per 0.1 unit increase.
cHazard ratios for continuous variable are per 100 unit increase.
The cumulative incidence of PJP was 1.7% (95% CI 0.8%–3.3%, at maximum follow-up of 2.5 years) after the start of bendamustine (n = 8 PJP events overall). Figure 1 depicts the cumulative incidence of PJP from the first administration up to 2.5 years after bendamustine. PJP was diagnosed at a median of 166.5 (range 14–218) days after initiation of bendamustine. Table 4 displays details about the patients diagnosed with PJP. Two patients were admitted to the ICU following PJP diagnosis (patients #4 and #7), and one patient died as a result of PJP (patient #8). Patient #4 was on clinical trial with bendamustine, obinutuzumab, and venetoclax. She presented with severe hyponatremia and bilateral pulmonary infiltrates consistent with a multifocal pneumonia. Over the course of her hospitalization she had witnessed aspiration on tube feeds with worsening hypoxia and tachypnea. She was transferred to the ICU, intubated, and subsequently suffered cardiac arrest with return of spontaneous circulation after 2 min of advanced cardiac life support. Lumber puncture and bronchoscopy demonstrated findings consistent with cytomegalovirus encephalitis and PJP. Patient’s neurological status did not improve, and the patient was compassionately extubated on day eight of her ICU admission. Death was determined to be a result of neurological compromise related to cytomegalovirus infection. Patient #7 was admitted to the ICU for mild PJP and hyperkalemia, which resolved with discontinuation of trimethoprim-sulfamethoxazole (TMP/SMX) treatment. The patient was switched to atovaquone therapy for PJP and transferred to a medical floor within 48 hours of ICU admission. Patient #8 was diagnosed with PJP and started on intravenous clindamycin and oral primaquine due to a severe sulfa allergy while hospitalized. Due to her malignancy and other comorbidities, she opted to transfer to hospice care without antimicrobial treatment for PJP, and subsequently died within a month of PJP diagnosis.
Enlarge this image.FIGURE 1. Cumulative incidence of Pneumocystis jirovecii pneumonia from the first administration up to 2.5 years after bendamustine
TABLE 4 Characteristics of patients on bendamustine who developed PJP
| No. | Age | Sex | Diagnosis | Stage | Other Treatment in Regimen | Line of Therapy | Cumulative Bendamustine Dose (mg/m2) | Timing of PJP | Source Tested | Treatment | ICU | Death due to PJP |
| 1 | 36 | F | Hodgkin’s lymphoma | Unstaged | Methylprednisolone | 4 | 760 | 64 days post-treatment | BAL | TMP/SMX (IV) | No | No |
| 2 | 53 | F | Angioimmunoblastic T-cell lymphoma | IV | Methylprednisolone | 8 | 987 | 59 days post-treatment | BAL | Atovaquone | No | No |
| 3 | 60 | M | Follicular lymphoma | IV | Rituximab | 1 | 1080 | 43 days post-treatment | Sputum | SMX-TMP (PO) | No | No |
| 4 | 66 | F | Follicular lymphoma | IV |
Obinutuzumab Venetoclax |
1 | 1080 | 78 days post-treatment | BAL | TMP/SMX (IV) | Yesa | No |
| 5 | 72 | M | Multiple myeloma | Unstaged | Dexamethasone | 7 | 100 | 148 days post-treatment | BAL | Pentamidine (IV), then TMP/SMX (IV) | No | No |
| 6 | 72 | M | Follicular lymphoma | III | Rituximab | 1 | 540 | Cycle 3 | BAL | TMP/SMX (PO) | No | No |
| 7 | 75 | M | Peripheral T-cell lymphoma | IV | None | 4 | 180 | Cycle 1 | BAL | TMP/SMX (PO), then Atovaquone | Yesb | No |
| 8 | 76 | F | Mantle cell lymphoma | IV | Rituximab | 1 | 540 | Cycle 3 | Sputum |
Clindamycin (IV) Primaquine (PO) |
No | Yesc |
Abbreviations: BAL, bronchoalveolar lavage; ICU, intensive care unit; IV, intravenous; PJP, Pneumocystis jirovecii pneumonia; PO, oral TMP/SMX, trimethoprim-sulfamethoxazole.
aPatient presented with severe hyponatremia and bilateral pulmonary infiltrates. Over the course of her hospitalization she had aspiration on tube feeds with worsening hypoxia and tachypnea. She was transferred to the ICU, intubated, and suffered cardiac arrest with return of spontaneous circulation after two minutes of advanced cardiac life support. Lumber puncture and bronchoscopy demonstrated cytomegalovirus encephalitis and PJP. Patient’s status did not improve, and the patient was compassionately extubated on day eight of her ICU admission. Death was determined to be a result of neurological compromise related to cytomegalovirus infection.
bAdmission lasting <48 h.
cPatient was started on intravenous clindamycin and oral primaquine due to a severe sulfa allergy while hospitalized. Patient refused to continue antimicrobial treatment for PJP and subsequently died as a result of PJP within a month of PJP diagnosis.
Anti-Pneumocystis prophylaxis was prescribed to 144 (29.6%) patients during the treatment and observation period and was at the discretion of the treating physician. The most commonly prescribed agent was TMP/SMX (n = 124, 86.1%), followed by inhaled pentamidine (n = 31, 21.5%). One of the eight patients who developed PJP was prescribed anti-Pneumocystis prophylaxis during bendamustine therapy. This patient (patient #2) developed a mild PJP infection despite receiving inhaled pentamidine as prophylaxis. She was successfully treated with atovaquone without any complications. A month later, the patient underwent allogeneic SCT. Prophylaxis was not significantly associated with a reduction in the development of PJP when compared no prophylaxis (HR 0.37, 95% CI (0.05, 3.04), p = 0.36). The Aalen–Johansen method was also used to estimate the cumulative incidence of PJP in the subset of patients who did not receive any anti-Pneumocystis prophylaxis during the study period (Figure 2). In this subset, the cumulative incidence of PJP was 2.1% (95% CI 1.0%–4.3%, at maximum follow-up of 2.5 years), after the start of bendamustine (n = 7 PJP events overall).
Enlarge this image.FIGURE 2. Cumulative incidence of Pneumocystis jirovecii pneumonia in patients who did not receive anti-Pneumocystis prophylaxis at any time from the first administration up to 2.5 years after bendamustine
Our study identified a cumulative incidence of PJP diagnosed by PCR of 1.7% in patients on bendamustine therapy. Anti-Pneumocystis prophylaxis was provided at the discretion of the treating physician to 29.6% of patients who received bendamustine-based regimens during the study period; however, use of prophylaxis was not found to be associated with a decreased incidence of PJP. Prior SCT and prior chemotherapy within 1 year of bendamustine were found to be significantly associated with a diagnosis of PJP. Of the eight patients who developed PJP, two were admitted to the ICU and one death was attributed to PJP.
Anti-Pneumocystis prophylaxis has historically been recommended when the incidence of PJP is greater than 3.5%.7–9 As our observed incidence and 95% confidence interval bands fell below this threshold, adverse events associated with prophylaxis would likely outweigh the benefit in most patients. We anticipated prophylaxis may be warranted in patients receiving bendamustine based on the known prolonged effect of bendamustine on CD4+ counts; however, this known physiological effect did not result in high rates of PJP in our cohort of patients.15,16,18,20 CD4+ data was not readily available for the included patient cohort, limiting further investigation into the explanation for observed PJP rates.
While information on the incidence of PJP in patients on bendamustine is limited, there are several case reports that describe PJP in a variety of immunocompromised patients.13–19 Additionally, while recent clinical trials involving patients receiving bendamustine have reported infectious episodes, few comment specifically on the occurrence of PJP.30–34 The phase II CONTRALTO trial, which included patients relapsed/refractory follicular lymphoma, reported PJP in three (6.1%) patients on bendamustine and rituximab plus venetoclax without any cases of PJP in either the bendamustine and rituximab or the venetoclax and rituximab arms for an overall incidence of 3/151 (1.99%) across the three groups.30 In an investigation of bendamustine, lenalidomide, and rituximab therapy in patients with mantle cell lymphoma, anti-Pneumocystis prophylaxis was not initially recommended; however, when a patient developed PJP on trial, TMP/SMX was prescribed to patients following a protocol amendment.31 Sustained reduction of CD4+ counts occurred in this trial; however, investigators also noted that the addition of prednisone during the induction may have contributed to the high incidence of opportunistic infections, including PJP.31 These findings demonstrate a variable PJP rate when prescribing a combination of antineoplastic or immunosuppressive agents with bendamustine. Concurrent chemotherapy, not including steroids, was not associated with an increased risk of PJP in our study. This is potentially explained by the overwhelming majority of patients receiving rituximab as the concurrent treatment with rituximab-based combination chemotherapy for B-cell lymphoma. Individual studies and a systematic review and meta-analysis using various databases have demonstrated a low overall incidence of PJP in the setting of rituximab-inclusive treatments.35–37 Due to the retrospective nature of this work, it is impossible to determine if this finding represents selection bias by providers who may have been less inclined to prescribe aggressive, intensive combination chemotherapy to patients with comorbid conditions and a potential higher baseline risk for infectious complications. Univariate analysis incorporating steroids into chemotherapy was impossible as it would include nearly every patient in our cohort and the low overall incidence of PJP in our patient cohort precluded multivariable analysis to assess if there was additional risk conferred by any particular bendamustine-based combination regimen.
Agents commonly used for prophylaxis have considerable adverse event profiles. One meta-analysis evaluated TMP/SMX when used for anti-Pneumocystis prophylaxis and found the rate of discontinuation for adverse events to be 15.2%. The rate of discontinuation for serious adverse events was 3.1%.7 Avoidance of unnecessary prophylaxis will decrease rates of adverse events, such as rash, myelosuppression, and anaphylaxis, while also reducing the patient’s pill burden. The recommendation against anti-Pneumocystis prophylaxis in this patient population is further supported by our finding that use of prophylaxis was not associated with a significant reduction in risk of developing PJP based on univariate analysis. We did, however, identify certain baseline characteristics that may predispose patients to an increased risk of PJP.
Patients who have undergone SCT are at high risk for opportunistic infections and literature has demonstrated that this risk is not confined to the immediate post-transplant period.38 A recently published investigation compared the incidence of infections occurring two or more years after SCT to matched cancer patients who did not undergo SCT and patients within the general population. PJP was significantly more common in the SCT group.39 Prior SCT was found to be associated with development of PJP in our cohort with three of the eight (37.5%) patients diagnosed with PJP having a history of SCT (autologous in patients #1 and #5, allogeneic in patient #2) occurring between 1 and 3 years prior to the initiation of bendamustine. These three patients had extensive chemotherapy treatment histories, including four to eight lines of chemotherapy prior to the initiation of bendamustine therapy in addition to the SCT; however, the number of preceding lines of chemotherapy was not found to be significantly associated with a diagnosis of PJP in our cohort. It may be reasonable to use anti-Pneumocystis prophylaxis in patients on bendamustine-based regimens with a history of SCT.
The large SEER-Medicare cohort reported that PJP risk was increased in those who received bendamustine for third-line therapy, but not first- or second-line treatment.23 The low number of PJP events in our cohort precluded us from determining if there was a statistically significant association of PJP with line of therapy; however, prior chemotherapy within 1 year of bendamustine initiation was found to be associated with development of PJP in our cohort. Of the eight patients who developed PJP, four were treated with chemotherapy within the year prior to initiating bendamustine. For these four patients, regimens immediately prior to bendamustine included bortezomib, doxorubicin, and dexamethasone; sorafenib and everolimus; vorinostat, cyclosporine, and dexamethasone; and gemcitabine, dexamethasone, and cisplatin. Recent chemotherapy is another important consideration where anti-Pneumocystis prophylaxis in patients on bendamustine-based regimens may be warranted.
This study has several limitations worth mentioning with the first being its single-center, retrospective, non-randomized design. We included patients over a substantial timeframe to attempt to overcome this limitation and achieve a representative sample. Second, there is the potential to achieve a positive result with Pneumocystis PCR in the setting of colonization. While the PCR assay has been designed to minimize this occurrence, we reviewed patient records for clinical signs and symptoms consistent with a diagnosis of PJP to confirm the accuracy of diagnosis. Third, we were unable to determine the dose and duration of steroids used during the study period as well as the temporal correlation to PJP diagnosis. The dose and duration of concomitant steroids should be considered in patients receiving bendamustine therapy to guide the use of PJP prophylaxis; however, we were unable to determine whether PJP prophylaxis would be warranted outside of the standard recommendations for patients on steroids in patients also receiving bendamustine. Finally, a substantial number of patients within our cohort received anti-Pneumocystis prophylaxis. This decision was made at the discretion of individual providers in the absence of specific recommendations for prophylaxis in this patient population. It was not possible to verify that patients were taking prophylactic medications as prescribed.
The cumulative incidence of PJP for patients on bendamustine therapy was 1.7% (95% CI 0.8%–3.3%) falling below the conventional 3.5% threshold for prophylaxis. The low incidence of PJP in this cohort of patients, including in those patients who did not receive anti-Pneumocystis prophylaxis, suggests that most patients on bendamustine therapy do not require routine prophylaxis. Patients with a history of SCT or who received additional chemotherapy within the year prior to bendamustine initiation may benefit from prophylaxis, but an optimal strategy must be further defined.
CONFLICT OF INTERESTThe authors declare no competing financial interests.
AUTHOR CONTRIBUTIONSConceptualization and methodology: MLR, JNB, CAT, KCM, PKT, ALP; Data curation, formal analysis, and interpretation: MLR, JNB, CAT, KCM, PKT, ALP; Writing – original draft: MLR, JNB, KCM; Writing – review and editing: MLR, JNB, CAT, KCM, PKT, ALP.
ETHICAL APPROVAL STATEMENTThe study was reviewed by the local Institutional Review Board (IRB) and determined to be exempt from the requirement for IRB approval (IRB #19-007217, Approval Date: September 20, 2019). After inclusion, an electronic health record (EHR) review was performed in accordance with the ethical standards of the 1964 Declaration of Helsinki with adherence to all relevant regulations of the US Health Insurance Portability and Accountability Act.
DATA AVAILABILITY STATEMENTThe data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.
© 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Details
; Barreto, Jason N 1
; Thompson, Carrie A 2
; Mara, Kristin C 3
; Tosh, Pritish K 4
; Limper, Andrew H 5
1 Department of Pharmacy, Mayo Clinic, Rochester, MN, USA
2 Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
3 Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA
4 Division of Infectious Diseases, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
5 Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA